Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
mTOR Market: Competitive Landscape, Pipeline, and Market Analysis 2022
mTOR Market: Competitive Landscape, Pipeline, and Market Analysis 2022
mTOR, or mammalian target of rapamycin, is a protein kinase that plays a crucial role in regulating cellular processes such as growth, metabolism, and survival. It acts as a central hub in signaling pathways, integrating various signals from growth factors, nutrients, and energy levels. The mechanism of action of mTOR involves the activation of downstream targets involved in protein synthesis, cell cycle progression, and autophagy. Dysregulation of mTOR signaling has been implicated in numerous diseases, leading to the development of mTOR inhibitors for therapeutic purposes. These inhibitors are utilized in the treatment of various indications, including cancer, neurodegenerative disorders, metabolic diseases, and certain renal and pulmonary conditions. According to the World Health Organization (WHO), cancer is a significant health concern in both Europe and the USA, in Europe, there are an estimated 3.9 million new cases of cancer annually, leading to 1.9 million deaths. The USA also experiences a high burden of cancer, with approximately 1.8 million new cases and 600,000 deaths each year, according to the Centers for Disease Control and Prevention (CDC). Furthermore, neurodegenerative disorders such as Alzheimer's and Parkinson's disease affect a substantial portion of the population in both regions. In Europe, over 10 million people suffer from Alzheimer's disease, while in the USA, Parkinson's disease affects approximately one million individuals, as reported by Alzheimer Europe and the Parkinson's Foundation, respectively.
The growth drivers of the mTOR market can be attributed to several factors. Firstly, the increasing prevalence of cancer and neurodegenerative disorders worldwide creates a significant demand for effective treatments, driving the adoption of mTOR inhibitors. Secondly, advancements in precision medicine and personalized therapies have led to the development of targeted approaches, where mTOR inhibitors play a vital role. Companies such as Abbott, Pfizer, Medtronic Bayer, GSK, Avalo Therap, Novartis, BMS, Kazia, Santen, Sanofi, and PIQUR cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, GSK is one such company that is currently conducting a clinical trial of the drug Omipalisib (GSK2126458) for the treatment of idiopathic pulmonary fibrosis.
Key Developments:
In May 2022, Medinol completed a phase III trial OF Ridaforolimus in Coronary artery restenosis in Japan.
In April 2023, Celcuity presented pharmacodynamics data of Gedatolisib from a preclinical study in Cancer at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Approved mTOR molecules
mTOR Pipeline Molecules
Clinical Activity and Development of mTOR
In the mTOR space, more than 30 companies are conducting more than 800 clinical trials in this category of drugs. For instance,
|
Product Name |
Total Studies |
|
Vistusertib (AZD2014) |
36 |
|
Dactolisib (RTB101) |
31 |
|
Gedatolisib (PF-05212384) |
22 |
|
Samotolisib (LY3023414) |
17 |
|
Paxalisib (GDC-0084) |
12 |
|
Voxtalisib (SAR245409) |
11 |
|
Bimiralisib (PQR309) |
9 |
|
Niclosamide topical (ATx 201) |
7 |
|
ABTL0812 |
5 |
|
AZD8055 |
5 |
|
ETP-47187 |
5 |
|
PF-04691502 |
5 |
|
SEL-110 |
5 |
|
ME-344 |
4 |
|
SF1126 |
4 |
|
SPN-820 |
4 |
|
Niclosamide (FW-1022) |
3 |
|
Omipalisib (GSK2126458) |
3 |
|
AVTX-006 |
2 |
|
BGT226 |
2 |
mTOR inhibitors are a class of drugs that target the mechanistic target of the rapamycin (mTOR) pathway, which plays a crucial role in regulating cell growth, metabolism, and survival. These drugs have shown promise in various indications, including cancer, autoimmune diseases, and neurological disorders. By inhibiting mTOR signaling, these drugs can impede the abnormal proliferation and survival of cancer cells, suppress immune responses in autoimmune diseases, and modulate neuronal activity in neurological disorders. Additionally, mTOR inhibitors have been investigated for their potential anti-aging effects and as therapeutic options for metabolic disorders. Their ability to target the mTOR pathway makes them an attractive treatment option for a wide range of diseases.
The global mTOR market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US regional market analysis of mTOR inhibitors reveals a robust and promising landscape. With a significant presence of pharmaceutical and biotechnology companies, the US market for mTOR drugs is highly competitive and well-established. The market is primarily driven by factors such as the rising incidence of cancer and the increasing prevalence of autoimmune diseases and neurological disorders. Additionally, the growing aging population, advancements in precision medicine, and the availability of favorable reimbursement policies further contribute to market growth. The presence of leading research institutions and healthcare facilities in the US also facilitates clinical trials and accelerates drug development in the mTOR space, fostering the expansion of the market. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for mTORs. These countries are increasingly adopting mTORs due to their efficacy and potential to improve patient outcomes. On the other hand, the mTOR market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the mTOR market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
mTOR drugs are used in the management of cancer, autoimmune diseases, and neurological disorders.
The market is primarily driven by factors such as the rising incidence of cancer and the increasing prevalence of autoimmune diseases and neurological disorders. Additionally, the growing aging population, advancements in precision medicine, and the availability of favorable reimbursement policies further contribute to market growth.
The major players in this space are First Wave Bio, Bayer, GSK, Avalo Therap, Novartis, BMS, Diffusion Pharma, Zhejiang DTRM Biopharma, HEC Pharm, Kazia, Santen, Sanofi, PIQUR, UNION Therap, Palvella Therapeutics, Ability Pharma, CNIO, REVA Medical, Nobelpharma, Selecta, Daewoong Pharma, MEI, SignalRx, Navitor Pharma, and Emtora Biosci.
Despite favorable market conditions, the mTOR drug market faces certain restraints. One major challenge is the high cost of mTOR inhibitors, which can limit access for patients and strain healthcare budgets. Additionally, the potential side effects and toxicity associated with mTOR inhibitors pose concerns for both patients and healthcare providers, requiring careful monitoring and management during treatment.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.